<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:07:57Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7393787" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7393787</identifier>
        <datestamp>2020-08-01</datestamp>
        <setSpec>annalsats</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Ann Am Thorac Soc</journal-id>
              <journal-id journal-id-type="publisher-id">AnnalsATS</journal-id>
              <journal-title-group>
                <journal-title>Annals of the American Thoracic Society</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2329-6933</issn>
              <issn pub-type="epub">2325-6621</issn>
              <publisher>
                <publisher-name>American Thoracic Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7393787</article-id>
              <article-id pub-id-type="pmcid">PMC7393787</article-id>
              <article-id pub-id-type="pmc-uid">7393787</article-id>
              <article-id pub-id-type="pmid">32425051</article-id>
              <article-id pub-id-type="pmid">32425051</article-id>
              <article-id pub-id-type="publisher-manuscript">202004-309SD</article-id>
              <article-id pub-id-type="doi">10.1513/AnnalsATS.202004-309SD</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Study Design</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Hydroxychloroquine versus Azithromycin for Hospitalized Patients with
Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label,
Active Comparator Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1206-6261</contrib-id>
                  <name>
                    <surname>Brown</surname>
                    <given-names>Samuel M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="author-notes" rid="fn1">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1730-234X</contrib-id>
                  <name>
                    <surname>Peltan</surname>
                    <given-names>Ithan D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1799-3315</contrib-id>
                  <name>
                    <surname>Webb</surname>
                    <given-names>Brandon</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kumar</surname>
                    <given-names>Naresh</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Starr</surname>
                    <given-names>Nathan</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Grissom</surname>
                    <given-names>Colin</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9505-2572</contrib-id>
                  <name>
                    <surname>Buckel</surname>
                    <given-names>Whitney R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff7">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Srivastava</surname>
                    <given-names>Raj</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff8">
                    <sup>8</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff9">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harris</surname>
                    <given-names>Estelle S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Leither</surname>
                    <given-names>Lindsay M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Johnson</surname>
                    <given-names>Stacy A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff10">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Paine</surname>
                    <given-names>Robert</given-names>
                    <suffix>III</suffix>
                  </name>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Greene</surname>
                    <given-names>Tom</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff11">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Pulmonary and Critical Care Medicine</aff>
                <aff id="aff3"><label><sup>3</sup></label>Infectious Disease, and</aff>
                <aff id="aff6"><label><sup>6</sup></label>Hospital Medicine, Intermountain Medical
Center, Murray, Utah</aff>
                <aff id="aff2"><label><sup>2</sup></label>Pulmonary and Critical Care Medicine</aff>
                <aff id="aff4"><label><sup>4</sup></label>Infectious Disease</aff>
                <aff id="aff9"><label><sup>9</sup></label>Inpatient Medicine, Department of
Pediatrics</aff>
                <aff id="aff10"><label><sup>10</sup></label>Hospital Medicine, and</aff>
                <aff id="aff11"><label><sup>11</sup></label>Biostatistics, University of Utah, Salt
Lake City, Utah</aff>
                <aff id="aff5"><label><sup>5</sup></label>Infectious Disease, Stanford University,
Stanford, California; and</aff>
                <aff id="aff7"><label><sup>7</sup></label>Pharmacy Services and</aff>
                <aff id="aff8"><label><sup>8</sup></label>Healthcare Delivery Institute,
Intermountain Healthcare, Murray, Utah</aff>
              </contrib-group>
              <author-notes>
                <corresp>Correspondence and requests for reprints should be addressed to Samuel M.
Brown, M.D., M.S., Intermountain Medical Center, 5121 S. Cottonwood Street,
Murray, UT 84107. E-mail: <email xlink:href="samuel.brown@imail.org">samuel.brown@imail.org</email>.</corresp>
                <fn id="fn1">
                  <label>*</label>
                  <p>S.M.B. is Associate Editor of <italic>AnnalsATS</italic>. His participation
complies with American Thoracic Society requirements for recusal from review
and decisions for authored works.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub-ppub">
                <month>8</month>
                <year>2020</year>
                <!--string-date: August 2020-->
              </pub-date>
              <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
              <pub-date pub-type="ppub">
                <month>8</month>
                <year>2020</year>
                <!--string-date: August 2020-->
              </pub-date>
              <pub-date pub-type="pmc-release">
                <month>8</month>
                <year>2020</year>
                <!--string-date: August 2020-->
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub-ppub"/>. -->
              <volume>17</volume>
              <issue>8</issue>
              <fpage>1008</fpage>
              <lpage>1015</lpage>
              <history>
                <date date-type="received">
                  <day>07</day>
                  <month>4</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>18</day>
                  <month>5</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2020 by the American Thoracic
Society</copyright-statement>
                <copyright-year>2020</copyright-year>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
                  <license-p>This article is open access and distributed under the terms of the
Creative Commons Attribution Non-Commercial No Derivatives License 4.0
(<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>). For
commercial usage and reprints, please contact Diane Gern (<email xlink:href="dgern@thoracic.org">dgern@thoracic.org</email>).</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="AnnalsATS.202004-309SD.pdf"/>
              <abstract>
                <p>Coronavirus disease (COVID-19) is a potentially fatal illness with no proven
therapy beyond excellent supportive care. Treatments are urgently sought.
Adaptations to traditional trial logistics and design to allow rapid
implementation, evaluation of trials within a global trials context, flexible
interim monitoring, and access outside traditional research hospitals (even in
settings where formal placebos are unavailable) may be helpful. Thoughtful
adaptations to traditional trial designs, especially within the global context
of related studies, may also foster collaborative relationships among
government, community, and the research enterprise. Here, we describe the
protocol for a pragmatic, active comparator trial in as many as 300 patients
comparing two current “off-label” treatments for
COVID-19—hydroxychloroquine and azithromycin—in academic and
nonacademic hospitals in Utah. We developed the trial in response to local
pressures for widespread, indiscriminate off-label use of these medications. We
used a hybrid Bayesian-frequentist design for interim monitoring to allow rapid,
contextual assessment of the available evidence. We also developed an inference
grid for interpreting the range of possible results from this trial within the
context of parallel trials and prepared for a network meta-analysis of the
resulting data. This trial was prospectively registered (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT04329832) before enrollment of
the first patient.</p>
                <p>Clinical trial registered with <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>
(NCT04329832).</p>
              </abstract>
              <kwd-group>
                <title>Keywords</title>
                <kwd>COVID-19</kwd>
                <kwd>clinical trial</kwd>
                <kwd>hydroxychloroquine</kwd>
              </kwd-group>
              <counts>
                <fig-count count="0"/>
                <table-count count="3"/>
                <page-count count="8"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p content-type="flushleft">In late 2019, a novel coronavirus, subsequently named severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on a genetic similarity to
the SARS coronavirus, was first observed to cause human illness (<xref rid="bib1" ref-type="bibr">1</xref>). The illness caused by SARS-CoV-2 was named coronavirus disease
(COVID-19). The clinical course of COVID-19 is highly variable. A majority of infected
patients experience a relatively benign course. However, in a significant number of
individuals, a viral pneumonia may occur, with high rates of hospitalization, acute
respiratory distress syndrome (ARDS), mechanical ventilation, and death (<xref rid="bib2" ref-type="bibr">2</xref>).</p>
            <p>To date, there is no reliable evidence regarding efficacy in COVID-19 for any therapy
beyond appropriate supportive care (<xref rid="bib3" ref-type="bibr">3</xref>).
Controlled trials of many proposed therapies are underway or imminently launching,
although many early trials in China were unable to accrue to target given delays in
launch combined with early efforts to control the epidemic there. These issues, as well
as previous disappointing experiences with Ebola, underscore the need for nimble,
timely, rigorous controlled trials in a pandemic setting (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>). However, active
community interest in such trials and their results may affect the range of trial
designs available, requiring both rigor and flexibility from trialists.</p>
            <p>Among many novel or repurposed medications proposed for the treatment of COVID-19, two
agents marketed in the United States have been prescribed hundreds of thousands or even
millions of times for other conditions: (hydroxy)chloroquine and azithromycin.
Chloroquine and hydroxychloroquine have been proposed as treatments for a broad range of
microorganisms, including viruses (<xref rid="bib6" ref-type="bibr">6</xref>). We review
the mechanisms of hydroxychloroquine and clinical results regarding its efficacy in the
online supplement. Briefly, hydroxychloroquine has <italic>in vitro</italic> efficacy
against multiple viruses but has never demonstrated clinical efficacy. Well-publicized
case series have been taken in public discussions to indicate clear evidence of clinical
efficacy. Public attention to hydroxychloroquine has been associated with subsequent
shortages and sometimes fatal overdoses (<xref rid="bib7" ref-type="bibr">7</xref>–<xref rid="bib10" ref-type="bibr">10</xref>).</p>
            <p>Governments have explored the possibility of widespread off-label use of
(hydroxy)chloroquine for treatment of COVID-19. However, the ubiquitous off-label use of
untested treatments blocks our ability to know whether they have efficacy, and may lack
adequate safety monitoring or informed consent. Academic, regulatory, and health
authorities have affirmed the need to avoid the use of hydroxychloroquine outside
clinical trials whenever possible (<xref rid="bib11" ref-type="bibr">11</xref>–<xref rid="bib14" ref-type="bibr">14</xref>).</p>
            <p>On the basis of data available at the time of trial launch, we believe that there are
compelling arguments for a randomized trial to evaluate the efficacy of
hydroxychloroquine in COVID-19. Given specific social and scientific circumstances, we
confronted the question of what kind of randomized trial to perform in the state of
Utah. Although placebo-controlled trials of proposed therapies for COVID-19 are in
various phases of planning or execution, such trials generally exclude patients treated
outside academic medical centers and may take weeks or months to launch, which may be
too late to enroll many patients during this pandemic, especially during its first major
wave. As large placebo-controlled trials of hydroxychloroquine and other agents in
academic centers (including our own) were preparing to launch, the investigators leading
the trial, representing the two major health systems in the state of Utah, were faced
with a dilemma. Some citizens and government officials in Utah sought immediate,
widespread administration of hydroxychloroquine without a physician’s
prescription (<xref rid="bib15" ref-type="bibr">15</xref>). The pressure to “do
something” was intense, and a meaningful response from local trialists was
exquisitely time sensitive.</p>
            <p>In addition to two quaternary referral centers, we are responsible for a large number of
other hospitals (<italic>n</italic> = 22), in most of which the
traditional research infrastructure is limited and patients may not have access to
placebo. Based on our urgent discussions with community members and local leaders, we
concluded that the state of Utah had little appetite for placebo or “usual
care” control arms among hospitalized patients. Practitioners were under
considerable pressure from patients and from the community to embrace off-label use of
agents viewed as potentially beneficial. Furthermore, we estimated (using current drug
par levels, projections, and external reports [<xref rid="bib7" ref-type="bibr">7</xref>–<xref rid="bib9" ref-type="bibr">9</xref>]) that drug supplies were
already or would soon be depleted by off-label use. We sought to offer patients
treatment as quickly as possible in a way that would prevent overuse of untested
medications with possible adverse effects while protecting the drug supply for patients
who depend on those drugs for their indicated conditions.</p>
            <p>In our response, we sought to be rigorous without being rigid. We designed a pragmatic
comparison of two common treatments for COVID-19 in a real-world setting, without the
timely availability of an identical placebo or blinding, and in a context where a
“usual care” or “standard of care” arm would be shifting
constantly and would be at high risk for contamination. We thus designed a pragmatic,
randomized, active comparator trial focused on nonacademic hospitals.</p>
            <p>As the active comparator, we chose azithromycin, a macrolide antibiotic with
antiinflammatory properties (and possibly some indirect antiviral effects [<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>])
and a longstanding, well-established safety record in a variety of conditions. Although
azithromycin is commonly recommended in combination with a β-lactam for
community-acquired pneumonia (which can be occasionally confused with COVID-19 during
the pandemic), evidence from a randomized trial suggests that omitting the macrolide is
in fact noninferior (<xref rid="bib18" ref-type="bibr">18</xref>). Azithromycin’s
pleiotropic antiinflammatory effects have been proposed to provide benefit in both
chronic and acute lung disease. In a secondary analysis of one ARDS trial
(<italic>N</italic> = 235), azithromycin was associated with
higher survival (<xref rid="bib19" ref-type="bibr">19</xref>), and a retrospective study
(with propensity matching) of 125 patients with sepsis-associated ARDS also suggested
lower 60-day mortality (<xref rid="bib20" ref-type="bibr">20</xref>). A secondary
analysis of a prospective observational cohort of patients with ARDS
(<italic>N</italic> = 873) suggested higher survival with
azithromycin (<xref rid="bib21" ref-type="bibr">21</xref>). In the AMAZES (Asthma and
Macrolides: the Azithromycin Efficacy and Safety) trial
(<italic>N</italic> = 420, 213 with azithromycin), chronic treatment
with azithromycin was associated with improvement in asthma symptoms. In that study,
gastrointestinal symptoms were the primary side effect (the only other adverse event
that may have differed from placebo was a 2% higher incidence of long QT, with no report
of cardiac arrhythmias) (<xref rid="bib22" ref-type="bibr">22</xref>). The WIZARD
(Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders) trial
attempted to prevent secondary cardiovascular events in 7,747 patients (3,879 randomized
to azithromycin) with coronary disease (a group at high risk for complications) but
showed no efficacy. The safety profile was excellent overall: other than a lower rate of
bacterial infections, only symptoms from the known gastrointestinal promotility effects
were observed. Although there was no significant decrease in mortality or coronary
events overall, the time-to-event curves may have favored azithromycin slightly (<xref rid="bib23" ref-type="bibr">23</xref>). Population-level retrospective studies have
provided conflicting evidence regarding an increase in the risk of sudden cardiac death
(vs. amoxicillin); however, the effect has not been observed in randomized trials,
suggesting that it may reflect indication bias rather than harm attributable to
azithromycin itself (<xref rid="bib24" ref-type="bibr">24</xref>–<xref rid="bib26" ref-type="bibr">26</xref>). Therefore, we believed that azithromycin was
potentially efficacious, with a very low likelihood of harm, and thus was an appropriate
comparator for hydroxychloroquine.</p>
            <p>In this paper, we provide details beyond the normal methodology for a study protocol,
given the complexity of operating nimbly and flexibly during a pandemic in a normally
inflexible regulatory environment and in collaboration with a state government. The
exponential spread of COVID-19 across the globe and the high rate of contagion,
especially in healthcare environments, make it necessary to have flexibility regarding
certain logistical details while maintaining the appropriate ethical and methodological
standards for clinical research. We began work on this trial on March 20, 2020, received
institutional review board approval on March 25, and enrolled the first patient on April
3.</p>
            <sec sec-type="methods">
              <title>Methods</title>
              <p content-type="flushleft">We designed a prospective, randomized, open-label, active
comparator trial of hydroxychloroquine versus azithromycin among hospitalized
patients with confirmed or suspected COVID-19.</p>
              <sec>
                <title>Target Population</title>
                <p content-type="flushleft">The eligibility criteria are displayed in <xref rid="tbl1" ref-type="table">Table 1</xref>. Conceptually, we seek to study
adult patients who are sick enough to require hospitalization and who are either
confirmed to have COVID-19 or are suspected to have COVID-19 with high clinical
probability. Details regarding the suspected COVID-19 criterion (including plans
to suspend it when testing results are quickly available) are presented in the
online supplement.</p>
                <table-wrap id="tbl1" orientation="portrait" position="float">
                  <label>Table 1.</label>
                  <caption>
                    <p>Eligibility criteria to define the target population of the trial</p>
                  </caption>
                  <!--OASIS TABLE HERE-->
                  <table frame="hsides" rules="groups">
                    <colgroup>
                      <col align="left"/>
                      <col align="center"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left">Criteria</th>
                        <th align="center">Rationales</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="2" align="left">Inclusion criteria<hr/></td>
                      </tr>
                      <tr>
                        <td align="left"> Age ≥18
yr</td>
                        <td align="left">Children have much
lower rates of severe COVID-19</td>
                      </tr>
                      <tr>
                        <td align="left"> Scheduled for
admission or already admitted to an inpatient
bed</td>
                        <td align="left">Hospitalized patients
have higher disease severity and may be most likely to
benefit from hydroxychloroquine</td>
                      </tr>
                      <tr>
                        <td align="left"> Confirmed or
suspected COVID-19<list list-type="simple"><list-item><p>Confirmed: positive assay for
COVID-19 within the last 10
d</p></list-item><list-item><p>Suspected: pending
assay for COVID-19 with high clinical
suspicion</p></list-item></list></td>
                        <td align="left">The treatments are
intended to improve outcomes from COVID-19; occasional
delays in turnaround time for testing might impede timely
treatment of patients with COVID-19</td>
                      </tr>
                      <tr>
                        <td colspan="2" align="left">Exclusion criteria<hr/></td>
                      </tr>
                      <tr>
                        <td align="left"> Allergy to
hydroxychloroquine or azithromycin</td>
                        <td align="left">High risk of adverse
events</td>
                      </tr>
                      <tr>
                        <td align="left"> History of bone
marrow transplant</td>
                        <td align="left">The study team believed
that bone marrow transplant clinicians would not allow
randomization of their patients in this trial, and that
immunity in his population is distinctive</td>
                      </tr>
                      <tr>
                        <td align="left"> Known G6PD
deficiency</td>
                        <td align="left">Theoretical concern
about hemolysis</td>
                      </tr>
                      <tr>
                        <td align="left"> Chronic
hemodialysis or glomerular filtration rate &lt;20
ml/min</td>
                        <td align="left">Package insert advises
increased risk of adverse effects</td>
                      </tr>
                      <tr>
                        <td align="left"> Psoriasis</td>
                        <td align="left">May cause worsening of
psoriasis</td>
                      </tr>
                      <tr>
                        <td align="left"> Porphyria</td>
                        <td align="left">May cause porphyria
crisis</td>
                      </tr>
                      <tr>
                        <td align="left"> Concomitant use
of digitalis, flecainide, amiodarone, procainamide,
propafenone, cimetidine, dofetilide, phenobarbital,
phenytoin, or sotalol</td>
                        <td align="left">Both agents may prolong
QT interval</td>
                      </tr>
                      <tr>
                        <td align="left"> History of long
QT syndrome</td>
                        <td align="left">Both agents may prolong
QT interval</td>
                      </tr>
                      <tr>
                        <td align="left"> Current known
QTc &gt;500 ms</td>
                        <td align="left">Both agents may prolong
QT interval</td>
                      </tr>
                      <tr>
                        <td align="left"> Seizure
disorder</td>
                        <td align="left">Hydroxychloroquine may
interfere with the function of antiepilepsy drugs or lower
the seizure threshold</td>
                      </tr>
                      <tr>
                        <td align="left"> Severe liver
disease</td>
                        <td align="left">Both drugs are
hepatically cleared</td>
                      </tr>
                      <tr>
                        <td align="left"> Outpatient use
of hydroxychloroquine or azithromycin for a chronic
condition or received more than 2 d of hydroxychloroquine or
azithromycin for suspected or confirmed
COVID-19</td>
                        <td align="left">Inappropriate to
randomize away from the indicated use of drugs or to give
overlapping courses of hydroxychloroquine or azithromycin
for COVID-19</td>
                      </tr>
                      <tr>
                        <td align="left"> Patient has
recovered from COVID-19 and/or is being discharged from the
hospital on the day of enrollment</td>
                        <td align="left">A physiological
rationale in this population is lacking; the probability of
benefit substantially decreased</td>
                      </tr>
                      <tr>
                        <td align="left"> Pregnant or
nursing</td>
                        <td align="left">Risk to fetus/infant.
Low numbers of potential participants of this profile would
limit investigators’ ability to understand efficacy
and safety in pregnant or nursing patients</td>
                      </tr>
                      <tr>
                        <td align="left"> Prisoner</td>
                        <td align="left">Concern to avoid
violation of autonomy</td>
                      </tr>
                      <tr>
                        <td align="left"> Weight &lt;35
kg</td>
                        <td align="left">Package insert advises
increased risk of adverse effects</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p><italic>Definition of abbreviation</italic>:
COVID-19 = coronavirus disease.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Study Procedures</title>
                <p content-type="flushleft">After informed consent is obtained (using the
“no-touch” techniques outlined in the online supplement), patients
will be randomized to one of two drug regimens in an open-label, randomized,
active comparator design. For enrolled patients whose laboratory test returns
negative for SARS-CoV-2, if the clinical team believes that another cause of the
patient’s presentation is more likely than COVID-19 in light of the
negative laboratory test, the clinical team will stop the study drug. Such
discontinuation will be recorded. Because the fundamental clinical question is
whether to start treatment in patients with confirmed or suspected COVID-19,
these patients will remain in the primary analytic cohort for efficacy and
safety. A secondary analytic cohort will include only those who test positive
for COVID-19.</p>
              </sec>
              <sec>
                <title>Study Drug</title>
                <p content-type="flushleft">Patients in the hydroxychloroquine arm will receive
hydroxychloroquine 400 mg by mouth twice a day for 1 day, and then 200 mg by
mouth twice a day for 4 days (<xref rid="bib27" ref-type="bibr">27</xref>) (with
dose reductions for weight &lt;45 kg or glomerular filtration rate &lt;50
ml/min). The drug dose chosen falls at the lower end of doses proposed in
various international trials, but it has proven <italic>in vitro</italic>
efficacy, with a ratio of lung tissue trough concentrations to the effective
concentration to suppress 50% of viral activity of &gt;20 (<xref rid="bib27" ref-type="bibr">27</xref>). Given <italic>in vitro</italic>
confirmation of the adequacy of the dose and the likely superior safety profile
at the lower dose, we chose the total dose of 2.4 g over 5 days for pragmatic
reasons.</p>
                <p>Patients in the azithromycin arm will receive azithromycin 500 mg on Day 1 plus
250 mg daily on Days 2–5 (administered orally or intravenously per the
clinician’s preference). Note: if the clinical attending physician
believes that bacterial pneumonia is likely and requires a second antibacterial
agent for “atypical” infection (an uncommon occurrence in
COVID-19), patients may receive another agent (e.g., doxycycline or
levofloxacin) as appropriate at the clinician’s discretion.</p>
                <p>For patients who received hydroxychloroquine or azithromycin immediately before
randomization (no more than 2 d before), prior doses will count toward the total
randomized dose.</p>
              </sec>
              <sec>
                <title>Adverse Event Monitoring and Medication Monitoring</title>
                <p content-type="flushleft">While patients are receiving the study medication, they
will be monitored remotely on a daily basis for <italic>1</italic>) the
development of adverse events and <italic>2</italic>) attempted introduction of
medications that may increase the risk of QT prolongation among study patients
(<italic>see</italic> the list in the online supplement). We are monitoring
daily for other medications that may prolong the QTc and will perform an
electrocardiogram (if one is not performed clinically) on study Day 2, after the
loading dose is administered. Treating teams will monitor electrolytes according
to standard clinical practice.</p>
              </sec>
              <sec>
                <title>Study Endpoints</title>
                <p content-type="flushleft">The primary endpoint is the World Health Organization
(WHO) COVID Ordinal Outcomes Scale at Day 14. The details of the endpoint are
displayed in <xref rid="tbl2" ref-type="table">Table 2</xref>.</p>
                <table-wrap id="tbl2" orientation="portrait" position="float">
                  <label>Table 2.</label>
                  <caption>
                    <p>World Health Organization COVID Ordinal Outcomes Scale<xref ref-type="table-fn" rid="tblfn1">*</xref></p>
                  </caption>
                  <!--OASIS TABLE HERE-->
                  <table frame="hsides" rules="groups">
                    <colgroup>
                      <col align="left"/>
                      <col align="center"/>
                      <col align="center"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left">Patient State</th>
                        <th align="center">Descriptor</th>
                        <th align="center">Score</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="2" align="left">Ambulatory</td>
                        <td align="left">No limitation of
activities</td>
                        <td align="center">1</td>
                      </tr>
                      <tr>
                        <td align="left">Limitation of
activities</td>
                        <td align="center">2</td>
                      </tr>
                      <tr>
                        <td rowspan="2" align="left">Hospitalized, mild disease</td>
                        <td align="left">No oxygen
therapy</td>
                        <td align="center">3</td>
                      </tr>
                      <tr>
                        <td align="left">Oxygen by mask or nasal
cannulae</td>
                        <td align="center">4</td>
                      </tr>
                      <tr>
                        <td rowspan="3" align="left">Hospitalized, severe disease</td>
                        <td align="left">Noninvasive ventilation
or high-flow oxygen</td>
                        <td align="center">5</td>
                      </tr>
                      <tr>
                        <td align="left">Invasive mechanical
ventilation without other organ support</td>
                        <td align="center">6</td>
                      </tr>
                      <tr>
                        <td align="left">Invasive mechanical
ventilation with other organ support (e.g., ECLS, CRRT, and
vasopressors)</td>
                        <td align="center">7</td>
                      </tr>
                      <tr>
                        <td align="left">Death</td>
                        <td align="left">Dead</td>
                        <td align="center">8</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p><italic>Definition of abbreviations</italic>:
COVID = coronavirus disease;
CRRT = continuous renal replacement therapy;
ECLS = extracorporeal life support.</p>
                    </fn>
                    <fn id="tblfn1">
                      <label>*</label>
                      <p>The score for the day reflects the worst status for the given
calendar day.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Secondary endpoints include hospital-free, ventilator-free, and intensive care
unit–free days, all at 28 days and all calculated as a worst-rank
ordinal, in which death is scored as −1 and the lowest score possible for
survivors is 0 (to limit survivorship bias [<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>]). We will use the
last-off method (only the time after the last liberation from, e.g., ventilation
counts toward the total number of -free days). We will also evaluate time to a
one-point decrease in the WHO COVID Ordinal Outcomes scale and the shape of the
WHO COVID Ordinal Outcomes scale over time.</p>
              </sec>
              <sec>
                <title>Ethical Considerations</title>
                <p content-type="flushleft">This protocol was reviewed and approved by the
institutional review board before the first patient was enrolled. A Data and
Safety Monitoring Board (DSMB) was formed, with the charter finalized and the
initial meeting held before study launch. Given the risk to research personnel,
and in the absence of guidance from the U.S. Food and Drug Administration or
Office for Human Research Protections regarding modifications to the Common Rule
or guidance for trialists, we developed a no-touch consenting approach
(reproduced in the online supplement) that allowed consent without direct
physical contact between patients (or their legally authorized representatives)
and research staff. (Our approach is consistent with subsequent guidance issued
by the Food and Drug Administration on March 27, 2020.)</p>
              </sec>
              <sec>
                <title>Rationale for an Active Comparator</title>
                <p content-type="flushleft">We anticipate that the absence of a placebo or
“usual care” control arm will be the most controversial design
element of this trial. In terms of actual placebo, we had no capacity to
manufacture or source a matching placebo in the time frame required for timely
trial launch, nor would many of our nonacademic hospitals have been able to
store or administer a placebo (lacking an investigational pharmacy).
Furthermore, we had a brief window of time in which to launch a trial that would
monitor patients closely and provide meaningful evidence to guide clinical care
and also be responsive to a community context in which state officials and even
some physicians felt an overriding imperative to provide hydroxychloroquine to
all patients.</p>
                <p>We also considered a “usual care” control arm. Even outside of a
pandemic setting, usual care control arms are known to be problematic given the
risk of variability, contamination, and decreases in trial efficiency (<xref rid="bib30" ref-type="bibr">30</xref>–<xref rid="bib33" ref-type="bibr">33</xref>). In the context of a pandemic, we anticipated that
usual care would shift frequently and that we would encounter substantial rates
of contamination (whether by one of the investigated agents or by differential
use of other untested therapies). Our decisions were also affected by
conversations about trial design with operational leaders and clinicians.</p>
                <p>We were also mindful of the global context of clinical trials during a pandemic
in which a rapid launch and simultaneous evaluation of multiple therapies are
high priorities (<xref rid="bib34" ref-type="bibr">34</xref>). Aware that
placebo-controlled trials of hydroxychloroquine were being performed or about to
be launched in academic centers (in addition to a global pragmatic trial led by
WHO), we anticipated that a trial comparing hydroxychloroquine with another
treatment commonly being administered would be of use to the global community.
This technique—the use of active comparators rather than placebo control
in a pandemic setting—has been used to good effect in Ebola. The PALM
(Pamoja Tulinde Maisha) Consortium trial allowed efficient prioritization of
novel monoclonal antibodies over an earlier antibody combination and antiviral
medication (<xref rid="bib35" ref-type="bibr">35</xref>). We note that a similar
approach is being used in COVID-19 for remdesivir: some trials (e.g.,
NCT04280705) use placebo controls, whereas others use two active arms (e.g.,
NCT04292899: 5 vs. 10 d of remdesivir). Importantly, the techniques of a network
meta-analysis provide the opportunity to integrate the results of our trial with
other trials in similar target populations, and we expect to use them (<xref rid="bib36" ref-type="bibr">36</xref>–<xref rid="bib38" ref-type="bibr">38</xref>).</p>
                <p>Other precedents are also relevant to our design decisions in the present trial.
Although comparative effectiveness research is often used to evaluate two
treatments that are widely known to be efficacious, more broadly it is a
framework for segmenting observed clinical care into units that can be compared
with each other. This technique has been used to compare targets for optimal
oxygen therapy (<xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>), targets for tidal volume in ARDS
(<xref rid="bib41" ref-type="bibr">41</xref>), positive end-expiratory
pressure targets in ARDS (<xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>), blood pressure targets for
hypotension (<xref rid="bib44" ref-type="bibr">44</xref>) or hypertension (<xref rid="bib45" ref-type="bibr">45</xref>), balanced crystalloids versus normal
saline (<xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>), and fluids versus vasopressors early in the course
of sepsis-associated hypotension (<xref rid="bib48" ref-type="bibr">48</xref>).
In each of these trials, several of which have appropriately changed clinical
practice, no “usual care” arm was included. Instead, two (or more)
common treatment strategies and/or medications were compared against each other.
Fundamentally, we pursued a similar pragmatic question: in the case of two
generally well tolerated treatments with considerable current clinical use
(off-label use that is depleting supplies of the drug for clinical use), is one
better than the other?</p>
                <p>We outline the anticipated interpretation of our trial, including three different
results from ongoing or imminently launching trials of hydroxychloroquine versus
placebo. We include an inference grid (<xref rid="tbl3" ref-type="table">Table
3</xref>) to describe our anticipated response to the possible outcomes of
the present trial, assuming that enrollment targets are met. We highlight the
fact that under most (but admittedly not all) circumstances, our trial will
offer a straightforwardly interpretable result. We also anticipate a network
meta-analysis in which our trial data are merged with trials that include
placebo arms in similar target populations.</p>
                <table-wrap id="tbl3" orientation="portrait" position="float">
                  <label>Table 3.</label>
                  <caption>
                    <p>Inference grid for interpretation of possible study outcomes in the
context of other trials</p>
                  </caption>
                  <!--OASIS TABLE HERE-->
                  <table frame="hsides" rules="groups">
                    <colgroup>
                      <col align="left"/>
                      <col align="center"/>
                      <col align="center"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left">Study Outcome</th>
                        <th align="center">Outcomes in Other
Trials of Hydroxychloroquine versus Placebo</th>
                        <th align="center">Expected
Inference</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="3" align="left">No
significant difference</td>
                        <td align="left">Unknown</td>
                        <td align="left">Neither agent is likely
to be efficacious; explore other options.</td>
                      </tr>
                      <tr>
                        <td align="left">Hydroxychloroquine not
efficacious</td>
                        <td align="left">Neither agent is
efficacious; explore other options.</td>
                      </tr>
                      <tr>
                        <td align="left">Hydroxychloroquine
efficacious</td>
                        <td align="left">Both agents are likely
efficacious; trials of combination therapy
indicated.</td>
                      </tr>
                      <tr>
                        <td rowspan="3" align="left">Hydroxychloroquine is significantly better than
azithromycin</td>
                        <td align="left">Unknown</td>
                        <td align="left">Hydroxychloroquine
should be preferred to azithromycin and is likely
efficacious.</td>
                      </tr>
                      <tr>
                        <td align="left">Hydroxychloroquine not
efficacious</td>
                        <td align="left">Azithromycin may have
unanticipated toxicities.</td>
                      </tr>
                      <tr>
                        <td align="left">Hydroxychloroquine
efficacious</td>
                        <td align="left">Hydroxychloroquine is
superior to azithromycin and is efficacious.</td>
                      </tr>
                      <tr>
                        <td rowspan="3" align="left">Azithromycin is significantly better than
hydroxychloroquine</td>
                        <td align="left">Unknown</td>
                        <td align="left">Hydroxychloroquine is
likely toxic and should not be recommended; azithromycin may
merit additional investigation.</td>
                      </tr>
                      <tr>
                        <td align="left">Hydroxychloroquine not
efficacious</td>
                        <td align="left">Hydroxychloroquine is
likely toxic and should not be recommended; azithromycin may
merit additional investigation.</td>
                      </tr>
                      <tr>
                        <td align="left">Hydroxychloroquine
efficacious</td>
                        <td align="left">Both hydroxychloroquine
and azithromycin are likely efficacious; combination therapy
should be investigated.</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
                <p>We emphasize that the probability of both treatments being efficacious, when
scores of treatments for viral pneumonia and similar syndromes have been tested
and found to lack clinical efficacy, is low. If, for example, we estimate that
hydroxychloroquine is a promising treatment, on the basis of prior trials of
promising treatments, it may have a 10% likelihood of a positive result for
clinical efficacy (which is probably high for the expected success rate in
similar clinical trials [<xref rid="bib49" ref-type="bibr">49</xref>]). Even if
azithromycin were similarly promising, the probability that both will be
efficacious (assuming independence) is 1%. We note that our intention is not to
use an occult placebo, even if there currently is greater interest in
hydroxychloroquine than in azithromycin. Azithromycin’s extensive
historic use in respiratory infections, and excellent safety record, provides a
reliable benchmark for hydroxychloroquine, a novel proposed therapeutic in
COVID-19 (a viral pneumonia).</p>
              </sec>
              <sec>
                <title>Statistical Considerations</title>
                <p content-type="flushleft">A formal statistical analysis plan (SAP) will be written
before the initial formal interim analysis is conducted. In the setting of
rapidly evolving knowledge concerning the COVID-19 pandemic, new information may
come to light that will necessitate subsequent modifications to the study
protocol and analyses; any such modifications will be documented and time
stamped. The principles of the SAP are outlined here, and an expanded version of
this summary is provided in the online supplement.</p>
                <sec>
                  <title>General</title>
                  <p content-type="flushleft">Descriptive summaries will be produced for relevant
variables. The primary analysis and analyses of secondary efficacy outcomes
will be performed in the intention-to-treat (ITT) population, which consists
of all randomized patients. Summaries of safety outcomes will be obtained
from a safety population consisting of all patients who receive at least one
dose of the study medication. We will also perform secondary analyses of
efficacy and safety within subsets of the intention-to-treat population
(especially those with positive COVID tests) and safety populations
restricted to patients who are confirmed to have COVID-19 (this approach has
been used in other trials, such as the VIOLET (Vitamin D to Improve Outcomes
by Leveraging Early Treatment) trial [<xref rid="bib50" ref-type="bibr">50</xref>]).</p>
                </sec>
                <sec>
                  <title>Primary analysis</title>
                  <p content-type="flushleft">The prespecified primary analysis will compare the
Day 14 assessment of the eight-level COVID Ordinal Outcomes Scale between
the randomized hydroxychloroquine and azithromycin groups. This analysis
will be performed using a proportional odds logistic regression model (<xref rid="bib51" ref-type="bibr">51</xref>), with the randomized treatment
group as the independent variable and patient age, comorbidities, and the
baseline level of the COVID Ordinal Outcomes Scale as covariates. The
proportional odds model is closely linked to the Wilcoxon rank-sums test
(<xref rid="bib52" ref-type="bibr">52</xref>) and is thus expected to
provide approximately valid inference even if the proportional odds
assumption is violated.</p>
                  <p>In accordance with a structure proposed by Harrell and Lindsell (<xref rid="bib53" ref-type="bibr">53</xref>), the primary analysis will be
performed using a Bayesian framework, with a somewhat conservative normal
prior distribution assumed for the log-transformed odds ratio. The prior
distributions for the intercept parameters and covariate regression
coefficients in the proportional odds model will be defined in the SAP. The
same Bayesian proportional odds model will be applied to the secondary
endpoints. Our primary analyses will be restricted to nonmissing
observations, without imputation, with sensitivity analyses using multiple
imputation if required by missingness.</p>
                </sec>
                <sec>
                  <title>Safety</title>
                  <p content-type="flushleft">The safety of both the hydroxychloroquine and
azithromycin treatments being evaluated in this study has been well
established in studies of thousands of patients and in postmarketing
surveillance. Nevertheless, we will evaluate the safety of these drugs in
the context of COVID-19 by providing counts (proportions) of adverse events,
with special attention to those listed in the package insert for
hydroxychloroquine and azithromycin, and careful investigation of any
serious and unexpected adverse events.</p>
                </sec>
                <sec>
                  <title>Interim monitoring</title>
                  <p content-type="flushleft">More details regarding interim monitoring are
provided in the online supplement. Under the Bayesian design, the posterior
distribution describing the accumulating evidence provided by the data for
treatment benefit or harm will be updated in successive interim analyses as
the trial proceeds (<xref rid="bib54" ref-type="bibr">54</xref>). Modifying
slightly the approach of Harrell and Lindsell, we will evaluate through
simulation the implications of given decision thresholds (<xref rid="bib55" ref-type="bibr">55</xref>). Final details on the interim
monitoring plan will be established in the DSMB charter before the first
interim analysis.</p>
                  <p>The general strategy would allow the trial to stop early for efficacy (in
either direction), but not for futility. Given the nature of the COVID-19
pandemic (with sudden and transient increases in patient volume in a given
location), it may be difficult for any single trial to answer a question
definitively on its own. We will also include feasibility evaluations to
allow us to determine when the first wave of COVID-19 has resolved, such
that further enrollment in the trial is unlikely. Given the potentially
cyclic nature of COVID-19, the DSMB, principal investigator, and trial
statistician may make a determination, given the totality of the evidence,
whether to suspend the trial if there is clear evidence that the first wave
is over in Utah, and secondarily whether to consider recurrent enrollment
(without release of results to investigators) in subsequent waves of
disease.</p>
                </sec>
                <sec>
                  <title>Sample size and power</title>
                  <p content-type="flushleft">Details regarding the power calculation are provided
in the online supplement. The target sample size of this trial is 300
randomized subjects, with a maximum detectable odds ratio (&lt;1,
suggesting efficacy of hydroxychloroquine over azithromycin) of 0.55, which
corresponds to a detectable risk ratio of 0.702. In any case, we anticipate
that the data from this study will meaningfully contribute to network
meta-analyses of therapeutics for COVID-19.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="conclusions">
              <title>Conclusions</title>
              <p content-type="flushleft">Faced with the prospect of massive statewide expansions of
clinical use of untested therapies with unknown risk/benefit profiles in COVID-19,
and operating within the context of global placebo-controlled trials being launched
in parallel, we initiated a pragmatic trial intended to both provide treatment
options in a structured environment, with informed consent and formal safety
monitoring, and contribute to knowledge about which treatment strategies may be of
use in subsequent waves of COVID-19 activity.</p>
            </sec>
          </body>
          <back>
            <ack>
              <sec>
                <title>Acknowledgment</title>
                <p>The authors thank Drs. Wesley Self and Matthew Semler for developing key
components of the ORCHID (Outcomes Related to COVID-19 treated with
Hydroxychloroquine among In-patients with symptomatic Disease) trial (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT04332991) that we integrated
into the HAHPS design (especially the data in the online supplement concerning
concomitant medications), and Drs. Frank Harrell and Chris Lindsell, who shared
their Bayesian analysis plan for ORCHID. They also thank the people of Utah, who
push us to be nimble and thoughtful.</p>
              </sec>
            </ack>
            <fn-group>
              <fn>
                <p>Supported by National Institute of General Medical Sciences (NIGMS) grant
K23GM129661 (I.D.P.). S.M.B. is supported by NHLBI grant R01HL144624. The HAHPS
trial is supported by the Intermountain Research and Medical Foundation and
departmental funds.</p>
              </fn>
              <fn>
                <p><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1513/AnnalsATS.202005-463ED">This article
has a related editorial</ext-link>.</p>
              </fn>
              <fn>
                <p>This article has an online supplement, which is accessible from this
issue’s table of contents at <ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org">www.atsjournals.org</ext-link>.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><underline><bold><ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org/doi/suppl/10.1513/AnnalsATS.202004-309SD/suppl_file/disclosures.pdf">Author disclosures</ext-link></bold></underline> are available with
the text of this article at <ext-link ext-link-type="uri" xlink:href="http://www.atsjournals.org">www.atsjournals.org</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bib1">
                <label>1 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhu</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Song</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>China Novel Coronavirus Investigating and Research Team</collab>
                  <article-title>A novel coronavirus from patients with pneumonia in China,
2019</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2020</year>
                  <volume>382</volume>
                  <fpage>727</fpage>
                  <lpage>733</lpage>
                  <pub-id pub-id-type="pmid">31978945</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>McGoogan</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Characteristics of and important lessons from the coronavirus
disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314
cases from the Chinese Center for Disease Control and
Prevention</article-title>
                  <source>
                    <italic>JAMA</italic>
                  </source>
                  <comment>[online ahead of print] 24 Feb 2020</comment>
                </mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Matthay</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Aldrich</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Gotts</surname>
                      <given-names>JE</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment for severe acute respiratory distress syndrome from
COVID-19</article-title>
                  <source>
                    <italic>Lancet Respir Med</italic>
                  </source>
                  <year>2020</year>
                  <volume>8</volume>
                  <fpage>433</fpage>
                  <lpage>434</lpage>
                  <pub-id pub-id-type="pmid">32203709</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kalil</surname>
                      <given-names>AC</given-names>
                    </name>
                  </person-group>
                  <article-title>Treating COVID-19-off-label drug use, compassionate use, and
randomized clinical trials during pandemics</article-title>
                  <source>
                    <italic>JAMA</italic>
                  </source>
                  <comment>[online ahead of print] 24 Mar 2020</comment>
                </mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5 </label>
                <mixed-citation publication-type="book">
                  <collab>National Academies of Sciences, Engineering, and Medicine</collab>
                  <source>
                    <italic>Integrating clinical research into epidemic response: the Ebola
experience.</italic>
                  </source>
                  <publisher-loc>Washington, DC</publisher-loc>
                  <publisher-name>National Academies Press</publisher-name>
                  <year>2017</year>
                </mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Savarino</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Boelaert</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Cassone</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Majori</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Cauda</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of chloroquine on viral infections: an old drug against
today’s diseases?</article-title>
                  <source>
                    <italic>Lancet Infect Dis</italic>
                  </source>
                  <year>2003</year>
                  <volume>3</volume>
                  <fpage>722</fpage>
                  <lpage>727</lpage>
                  <pub-id pub-id-type="pmid">14592603</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kim</surname>
                      <given-names>AHJ</given-names>
                    </name>
                    <name>
                      <surname>Sparks</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Liew</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Putman</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Berenbaum</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Duarte-García</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>COVID-19 Global Rheumatology Alliance†</collab>
                  <article-title>A rush to judgment? Rapid reporting and dissemination of results
and its consequences regarding the use of hydroxychloroquine for
COVID-19</article-title>
                  <source>
                    <italic>Ann Intern Med</italic>
                  </source>
                  <comment>[online ahead of print] 30 Mar 2020</comment>
                </mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8 </label>
                <mixed-citation publication-type="other">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Niforatos</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Johansen</surname>
                      <given-names>ME</given-names>
                    </name>
                  </person-group>
                  <article-title>Hydroxychloroquine use in the United States and the potential
impact of critical shortages from SARS-CoV-2</article-title>
                  <comment>Annals of Family Medicine, COVID-19 Collection. 2020 [accessed 2020 Jun
9]. Available from: <ext-link ext-link-type="uri" xlink:href="http://hdl.handle.net/2027.42/154736">http://hdl.handle.net/2027.42/154736</ext-link></comment>
                </mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Peschken</surname>
                      <given-names>CA</given-names>
                    </name>
                  </person-group>
                  <article-title>Possible consequences of a shortage of hydroxychloroquine for
patients with systemic lupus erythematosus amid the COVID-19
pandemic</article-title>
                  <source>
                    <italic>J Rheumatol</italic>
                  </source>
                  <comment>[online ahead of print] 8 Apr 2020</comment>
                </mixed-citation>
              </ref>
              <ref id="bib10">
                <label>10 </label>
                <mixed-citation publication-type="other">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shepherd</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>A man thought aquarium cleaner with the same name as the
anti-viral drug chloroquine would prevent coronavirus: it killed
him</article-title>
                  <italic>Washington Post</italic>
                  <year>2020</year>
                  <comment>March 24 [accessed 2020 Jun 9]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.washingtonpost.com/nation/2020/03/24/coronavirus-chloroquine-poisoning-death/">https://www.washingtonpost.com/nation/2020/03/24/coronavirus-chloroquine-poisoning-death/</ext-link></comment>
                </mixed-citation>
              </ref>
              <ref id="bib11">
                <label>11 </label>
                <mixed-citation publication-type="web">
                  <collab>Infectious Diseases Society of America</collab>
                  <article-title>Infectious Diseases Society of America guidelines on the
treatment and management of patients with COVID-19;</article-title>
                  <year>2020</year>
                  <comment>[accessed 2020 Apr 17]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/">https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</ext-link></comment>
                </mixed-citation>
              </ref>
              <ref id="bib12">
                <label>12 </label>
                <mixed-citation publication-type="web">
                  <collab>U.S. Food and Drug Administration</collab>
                  <article-title>Fact sheet for health care providers: emergency use authorization
(EUA) of hydroxychloroquine sulfate supplied from the strategic national
stockpile for treatment of COVID-19 in certain hospitalized
patients;</article-title>
                  <year>2020</year>
                  <comment>[accessed 2020 Jun 9]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/media/136537/download">https://www.fda.gov/media/136537/download</ext-link></comment>
                </mixed-citation>
              </ref>
              <ref id="bib13">
                <label>13 </label>
                <mixed-citation publication-type="book">
                  <collab>World Health Organization</collab>
                  <article-title>Clinical care for severe acute respiratory infection: toolkit:
COVID-19 adaptation</article-title>
                  <publisher-name>World Health Organization</publisher-name>
                  <year>2020</year>
                  <comment>[accessed 2020 Jun 9]. Available from: <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf">https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-eng.pdf</ext-link></comment>
                </mixed-citation>
              </ref>
              <ref id="bib14">
                <label>14 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alhazzani</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Møller</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Arabi</surname>
                      <given-names>YM</given-names>
                    </name>
                    <name>
                      <surname>Loeb</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Gong</surname>
                      <given-names>MN</given-names>
                    </name>
                    <name>
                      <surname>Fan</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Surviving Sepsis Campaign: guidelines on the management of
critically ill adults with coronavirus disease 2019
(COVID-19)</article-title>
                  <source>
                    <italic>Intensive Care Med</italic>
                  </source>
                  <year>2020</year>
                  <volume>46</volume>
                  <fpage>854</fpage>
                  <lpage>887</lpage>
                  <pub-id pub-id-type="pmid">32222812</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib15">
                <label>15 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roche</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>State setting up access to malaria drugs seen as treating new
coronavirus. Deseret News</article-title>
                  <year>2020</year>
                  <comment>[accessed 2020 Jun 9]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.deseret.com/utah/2020/3/23/21191657/coronavirus-covid-19-hydroxychloroquine-chloroquine-malaria-treatment-utah">https://www.deseret.com/utah/2020/3/23/21191657/coronavirus-covid-19-hydroxychloroquine-chloroquine-malaria-treatment-utah</ext-link></comment>
                </mixed-citation>
              </ref>
              <ref id="bib16">
                <label>16 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gielen</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Johnston</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Edwards</surname>
                      <given-names>MR</given-names>
                    </name>
                  </person-group>
                  <article-title>Azithromycin induces anti-viral responses in bronchial epithelial
cells</article-title>
                  <source>
                    <italic>Eur Respir J</italic>
                  </source>
                  <year>2010</year>
                  <volume>36</volume>
                  <fpage>646</fpage>
                  <lpage>654</lpage>
                  <pub-id pub-id-type="pmid">20150207</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib17">
                <label>17 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Menzel</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Akbarshahi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Bjermer</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Uller</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Azithromycin induces anti-viral effects in cultured bronchial
epithelial cells from COPD patients</article-title>
                  <source>
                    <italic>Sci Rep</italic>
                  </source>
                  <year>2016</year>
                  <volume>6</volume>
                  <fpage>28698</fpage>
                  <pub-id pub-id-type="pmid">27350308</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib18">
                <label>18 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Postma</surname>
                      <given-names>DF</given-names>
                    </name>
                    <name>
                      <surname>van Werkhoven</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>van Elden</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Thijsen</surname>
                      <given-names>SF</given-names>
                    </name>
                    <name>
                      <surname>Hoepelman</surname>
                      <given-names>AI</given-names>
                    </name>
                    <name>
                      <surname>Kluytmans</surname>
                      <given-names>JA</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>CAP-START Study Group</collab>
                  <article-title>Antibiotic treatment strategies for community-acquired pneumonia
in adults</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2015</year>
                  <volume>372</volume>
                  <fpage>1312</fpage>
                  <lpage>1323</lpage>
                  <pub-id pub-id-type="pmid">25830421</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib19">
                <label>19 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Walkey</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Wiener</surname>
                      <given-names>RS</given-names>
                    </name>
                  </person-group>
                  <article-title>Macrolide antibiotics and survival in patients with acute lung
injury</article-title>
                  <source>
                    <italic>Chest</italic>
                  </source>
                  <year>2012</year>
                  <volume>141</volume>
                  <fpage>1153</fpage>
                  <lpage>1159</lpage>
                  <pub-id pub-id-type="pmid">22116799</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib20">
                <label>20 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kawamura</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Ichikado</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Takaki</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sakata</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Yasuda</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Shingu</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Efficacy of azithromycin in sepsis-associated acute respiratory
distress syndrome: a retrospective study and propensity score
analysis</article-title>
                  <source>
                    <italic>Springerplus</italic>
                  </source>
                  <year>2016</year>
                  <volume>5</volume>
                  <fpage>1193</fpage>
                  <pub-id pub-id-type="pmid">27516931</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib21">
                <label>21 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Simonis</surname>
                      <given-names>FD</given-names>
                    </name>
                    <name>
                      <surname>de Iudicibus</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Cremer</surname>
                      <given-names>OL</given-names>
                    </name>
                    <name>
                      <surname>Ong</surname>
                      <given-names>DSY</given-names>
                    </name>
                    <name>
                      <surname>van der Poll</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Bos</surname>
                      <given-names>LD</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>MARS consortium</collab>
                  <article-title>Macrolide therapy is associated with reduced mortality in acute
respiratory distress syndrome (ARDS) patients</article-title>
                  <source>
                    <italic>Ann Transl Med</italic>
                  </source>
                  <year>2018</year>
                  <volume>6</volume>
                  <fpage>24</fpage>
                  <pub-id pub-id-type="pmid">29430441</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib22">
                <label>22 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gibson</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>IA</given-names>
                    </name>
                    <name>
                      <surname>Upham</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Reynolds</surname>
                      <given-names>PN</given-names>
                    </name>
                    <name>
                      <surname>Hodge</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>James</surname>
                      <given-names>AL</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Effect of azithromycin on asthma exacerbations and quality of
life in adults with persistent uncontrolled asthma (AMAZES): a randomised,
double-blind, placebo-controlled trial</article-title>
                  <source>
                    <italic>Lancet</italic>
                  </source>
                  <year>2017</year>
                  <volume>390</volume>
                  <fpage>659</fpage>
                  <lpage>668</lpage>
                  <pub-id pub-id-type="pmid">28687413</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib23">
                <label>23 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>O’Connor</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Dunne</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Pfeffer</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Muhlestein</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Yao</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Gupta</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>Investigators in the WIZARD Study</collab>
                  <article-title>Azithromycin for the secondary prevention of coronary heart
disease events: the WIZARD study: a randomized controlled
trial</article-title>
                  <source>
                    <italic>JAMA</italic>
                  </source>
                  <year>2003</year>
                  <volume>290</volume>
                  <fpage>1459</fpage>
                  <lpage>1466</lpage>
                  <pub-id pub-id-type="pmid">13129985</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib24">
                <label>24 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ray</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Murray</surname>
                      <given-names>KT</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Arbogast</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Stein</surname>
                      <given-names>CM</given-names>
                    </name>
                  </person-group>
                  <article-title>Azithromycin and the risk of cardiovascular death</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2012</year>
                  <volume>366</volume>
                  <fpage>1881</fpage>
                  <lpage>1890</lpage>
                  <pub-id pub-id-type="pmid">22591294</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib25">
                <label>25 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Strle</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Maraspin</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>Is azithromycin treatment associated with prolongation of the
Q-Tc interval?</article-title>
                  <source>
                    <italic>Wien Klin Wochenschr</italic>
                  </source>
                  <year>2002</year>
                  <volume>114</volume>
                  <fpage>396</fpage>
                  <lpage>399</lpage>
                  <pub-id pub-id-type="pmid">12708094</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib26">
                <label>26 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Svanström</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Pasternak</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Hviid</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Use of azithromycin and death from cardiovascular
causes</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2013</year>
                  <volume>368</volume>
                  <fpage>1704</fpage>
                  <lpage>1712</lpage>
                  <pub-id pub-id-type="pmid">23635050</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib27">
                <label>27 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yao</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Ye</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cui</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Niu</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title><italic>In vitro</italic> antiviral activity and projection of
optimized dosing design of hydroxychloroquine for the treatment of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</article-title>
                  <source>
                    <italic>Clin Infect Dis</italic>
                  </source>
                  <comment>[online ahead of print] 9 Mar 2020</comment>
                </mixed-citation>
              </ref>
              <ref id="bib28">
                <label>28 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Colantuoni</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Scharfstein</surname>
                      <given-names>DO</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Hashem</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Leroux</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Needham</surname>
                      <given-names>DM</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Statistical methods to compare functional outcomes in randomized
controlled trials with high mortality</article-title>
                  <source>
                    <italic>BMJ</italic>
                  </source>
                  <year>2018</year>
                  <volume>360</volume>
                  <fpage>j5748</fpage>
                  <pub-id pub-id-type="pmid">29298779</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib29">
                <label>29 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Novack</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Beitler</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Yitshak-Sade</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>BT</given-names>
                    </name>
                    <name>
                      <surname>Schoenfeld</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Rubenfeld</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Alive and ventilator free: a hierarchical, composite outcome for
clinical trials in the acute respiratory distress syndrome</article-title>
                  <source>
                    <italic>Crit Care Med</italic>
                  </source>
                  <year>2020</year>
                  <volume>48</volume>
                  <fpage>158</fpage>
                  <lpage>166</lpage>
                  <pub-id pub-id-type="pmid">31939783</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib30">
                <label>30 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thompson</surname>
                      <given-names>BT</given-names>
                    </name>
                    <name>
                      <surname>Schoenfeld</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Usual care as the control group in clinical trials of
nonpharmacologic interventions</article-title>
                  <source>
                    <italic>Proc Am Thorac Soc</italic>
                  </source>
                  <year>2007</year>
                  <volume>4</volume>
                  <fpage>577</fpage>
                  <lpage>582</lpage>
                  <pub-id pub-id-type="pmid">17878473</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib31">
                <label>31 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hart</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Harhay</surname>
                      <given-names>MO</given-names>
                    </name>
                    <name>
                      <surname>Gabler</surname>
                      <given-names>NB</given-names>
                    </name>
                    <name>
                      <surname>Ratcliffe</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Quill</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Halpern</surname>
                      <given-names>SD</given-names>
                    </name>
                  </person-group>
                  <article-title>Variability among US intensive care units in managing the care of
patients admitted with preexisting limits on life-sustaining
therapies</article-title>
                  <source>
                    <italic>JAMA Intern Med</italic>
                  </source>
                  <year>2015</year>
                  <volume>175</volume>
                  <fpage>1019</fpage>
                  <lpage>1026</lpage>
                  <pub-id pub-id-type="pmid">25822402</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib32">
                <label>32 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dean</surname>
                      <given-names>NC</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Aronsky</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Vines</surname>
                      <given-names>CG</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>BE</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Hospital admission decision for patients with community-acquired
pneumonia: variability among physicians in an emergency
department</article-title>
                  <source>
                    <italic>Ann Emerg Med</italic>
                  </source>
                  <year>2012</year>
                  <volume>59</volume>
                  <fpage>35</fpage>
                  <lpage>41</lpage>
                  <pub-id pub-id-type="pmid">21907451</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib33">
                <label>33 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Peltan</surname>
                      <given-names>ID</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>KH</given-names>
                    </name>
                    <name>
                      <surname>Rudd</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Carlbom</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Hough</surname>
                      <given-names>CL</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Physician variation in time to antimicrobial treatment for septic
patients presenting to the emergency department</article-title>
                  <source>
                    <italic>Crit Care Med</italic>
                  </source>
                  <year>2017</year>
                  <volume>45</volume>
                  <fpage>1011</fpage>
                  <lpage>1018</lpage>
                  <pub-id pub-id-type="pmid">28426466</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib34">
                <label>34 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Angus</surname>
                      <given-names>DC</given-names>
                    </name>
                  </person-group>
                  <article-title>Optimizing the trade-off between learning and doing in a
pandemic</article-title>
                  <source>
                    <italic>JAMA</italic>
                  </source>
                  <comment>[online ahead of print] 30 Mar 2020</comment>
                </mixed-citation>
              </ref>
              <ref id="bib35">
                <label>35 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mulangu</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Dodd</surname>
                      <given-names>LE</given-names>
                    </name>
                    <name>
                      <surname>Davey</surname>
                      <given-names>RT</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Tshiani Mbaya</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Proschan</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mukadi</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>PALM Writing Group</collab>
                  <collab>PALM Consortium Study Team</collab>
                  <article-title>A randomized, controlled trial of Ebola virus disease
therapeutics</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2019</year>
                  <volume>381</volume>
                  <fpage>2293</fpage>
                  <lpage>2303</lpage>
                  <pub-id pub-id-type="pmid">31774950</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib36">
                <label>36 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mills</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Thorlund</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Ioannidis</surname>
                      <given-names>JP</given-names>
                    </name>
                  </person-group>
                  <article-title>Demystifying trial networks and network
meta-analysis</article-title>
                  <source>
                    <italic>BMJ</italic>
                  </source>
                  <year>2013</year>
                  <volume>346</volume>
                  <fpage>f2914</fpage>
                  <pub-id pub-id-type="pmid">23674332</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib37">
                <label>37 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lumley</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Network meta-analysis for indirect treatment
comparisons</article-title>
                  <source>
                    <italic>Stat Med</italic>
                  </source>
                  <year>2002</year>
                  <volume>21</volume>
                  <fpage>2313</fpage>
                  <lpage>2324</lpage>
                  <pub-id pub-id-type="pmid">12210616</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib38">
                <label>38 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Song</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Xiong</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Parekh-Bhurke</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Loke</surname>
                      <given-names>YK</given-names>
                    </name>
                    <name>
                      <surname>Sutton</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Eastwood</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <article-title>Inconsistency between direct and indirect comparisons of
competing interventions: meta-epidemiological study</article-title>
                  <source>
                    <italic>BMJ</italic>
                  </source>
                  <year>2011</year>
                  <volume>343</volume>
                  <fpage>d4909</fpage>
                  <pub-id pub-id-type="pmid">21846695</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib39">
                <label>39 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Young</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Mackle</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Bailey</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Beasley</surname>
                      <given-names>RW</given-names>
                    </name>
                    <name>
                      <surname>Bennett</surname>
                      <given-names>VL</given-names>
                    </name>
                    <name>
                      <surname>Deane</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>The ICU-ROX pilot investigators</collab>
                  <collab>The Australian and New Zealand Intensive Care Society Clinical Trials
Group</collab>
                  <article-title>Intensive care unit randomised trial comparing two approaches to
oxygen therapy (ICU-ROX): results of the pilot phase</article-title>
                  <source>
                    <italic>Crit Care Resusc</italic>
                  </source>
                  <year>2017</year>
                  <volume>19</volume>
                  <fpage>344</fpage>
                  <lpage>354</lpage>
                  <pub-id pub-id-type="pmid">29202261</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib40">
                <label>40 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barrot</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Asfar</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Mauny</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Winiszewski</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Montini</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Badie</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>LOCO2 Investigators and REVA Research Network</collab>
                  <article-title>Liberal or conservative oxygen therapy for acute respiratory
distress syndrome</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2020</year>
                  <volume>382</volume>
                  <fpage>999</fpage>
                  <lpage>1008</lpage>
                  <pub-id pub-id-type="pmid">32160661</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib41">
                <label>41 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brower</surname>
                      <given-names>RG</given-names>
                    </name>
                    <name>
                      <surname>Matthay</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Morris</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Schoenfeld</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>BT</given-names>
                    </name>
                    <name>
                      <surname>Wheeler</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <collab>Acute Respiratory Distress Syndrome Network</collab>
                  <article-title>Ventilation with lower tidal volumes as compared with traditional
tidal volumes for acute lung injury and the acute respiratory distress
syndrome</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2000</year>
                  <volume>342</volume>
                  <fpage>1301</fpage>
                  <lpage>1308</lpage>
                  <pub-id pub-id-type="pmid">10793162</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib42">
                <label>42 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cavalcanti</surname>
                      <given-names>AB</given-names>
                    </name>
                    <name>
                      <surname>Suzumura</surname>
                      <given-names>ÉA</given-names>
                    </name>
                    <name>
                      <surname>Laranjeira</surname>
                      <given-names>LN</given-names>
                    </name>
                    <name>
                      <surname>Paisani</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Damiani</surname>
                      <given-names>LP</given-names>
                    </name>
                    <name>
                      <surname>Guimarães</surname>
                      <given-names>HP</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>Writing Group for the Alveolar Recruitment for Acute Respiratory
Distress Syndrome Trial (ART) Investigators</collab>
                  <article-title>Effect of lung recruitment and titrated positive end-expiratory
pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory
distress syndrome: a randomized clinical trial</article-title>
                  <source>
                    <italic>JAMA</italic>
                  </source>
                  <year>2017</year>
                  <volume>318</volume>
                  <fpage>1335</fpage>
                  <lpage>1345</lpage>
                  <pub-id pub-id-type="pmid">28973363</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib43">
                <label>43 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brower</surname>
                      <given-names>RG</given-names>
                    </name>
                    <name>
                      <surname>Lanken</surname>
                      <given-names>PN</given-names>
                    </name>
                    <name>
                      <surname>MacIntyre</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Matthay</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Morris</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ancukiewicz</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>National Heart, Lung, and Blood Institute ARDS Clinical Trials
Network</collab>
                  <article-title>Higher versus lower positive end-expiratory pressures in patients
with the acute respiratory distress syndrome</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2004</year>
                  <volume>351</volume>
                  <fpage>327</fpage>
                  <lpage>336</lpage>
                  <pub-id pub-id-type="pmid">15269312</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib44">
                <label>44 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lamontagne</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Richards-Belle</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Harrison</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Sadique</surname>
                      <given-names>MZ</given-names>
                    </name>
                    <name>
                      <surname>Grieve</surname>
                      <given-names>RD</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>65 Trial Investigators</collab>
                  <article-title>Effect of reduced exposure to vasopressors on 90-day mortality in
older critically ill patients with vasodilatory hypotension: a randomized
clinical trial</article-title>
                  <source>
                    <italic>JAMA</italic>
                  </source>
                  <year>2020</year>
                  <volume>323</volume>
                  <fpage>938</fpage>
                  <lpage>949</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib45">
                <label>45 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wright</surname>
                      <given-names>JT</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Williamson</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Whelton</surname>
                      <given-names>PK</given-names>
                    </name>
                    <name>
                      <surname>Snyder</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Sink</surname>
                      <given-names>KM</given-names>
                    </name>
                    <name>
                      <surname>Rocco</surname>
                      <given-names>MV</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>SPRINT Research Group</collab>
                  <article-title>A randomized trial of intensive versus standard blood-pressure
control</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2015</year>
                  <volume>373</volume>
                  <fpage>2103</fpage>
                  <lpage>2116</lpage>
                  <pub-id pub-id-type="pmid">26551272</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib46">
                <label>46 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Self</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Semler</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Wanderer</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>DW</given-names>
                    </name>
                    <name>
                      <surname>Collins</surname>
                      <given-names>SP</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>SALT-ED Investigators</collab>
                  <article-title>Balanced crystalloids versus saline in noncritically ill
adults</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2018</year>
                  <volume>378</volume>
                  <fpage>819</fpage>
                  <lpage>828</lpage>
                  <pub-id pub-id-type="pmid">29485926</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib47">
                <label>47 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Semler</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Self</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Wanderer</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Ehrenfeld</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>DW</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>SMART Investigators and the Pragmatic Critical Care Research
Group</collab>
                  <article-title>Balanced crystalloids versus saline in critically ill
adults</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2018</year>
                  <volume>378</volume>
                  <fpage>829</fpage>
                  <lpage>839</lpage>
                  <pub-id pub-id-type="pmid">29485925</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib48">
                <label>48 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Self</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Semler</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Bellomo</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>deBoisblanc</surname>
                      <given-names>BP</given-names>
                    </name>
                    <name>
                      <surname>Exline</surname>
                      <given-names>MC</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>CLOVERS Protocol Committee and NHLBI Prevention and Early Treatment of
Acute Lung Injury (PETAL) Network Investigators</collab>
                  <article-title>Liberal versus restrictive intravenous fluid therapy for early
septic shock: rationale for a randomized trial</article-title>
                  <source>
                    <italic>Ann Emerg Med</italic>
                  </source>
                  <year>2018</year>
                  <volume>72</volume>
                  <fpage>457</fpage>
                  <lpage>466</lpage>
                  <pub-id pub-id-type="pmid">29753517</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib49">
                <label>49 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wong</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>Siah</surname>
                      <given-names>KW</given-names>
                    </name>
                    <name>
                      <surname>Lo</surname>
                      <given-names>AW</given-names>
                    </name>
                  </person-group>
                  <article-title>Estimation of clinical trial success rates and related
parameters</article-title>
                  <source>
                    <italic>Biostatistics</italic>
                  </source>
                  <year>2019</year>
                  <volume>20</volume>
                  <fpage>273</fpage>
                  <lpage>286</lpage>
                  <pub-id pub-id-type="pmid">29394327</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib50">
                <label>50 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ginde</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Brower</surname>
                      <given-names>RG</given-names>
                    </name>
                    <name>
                      <surname>Caterino</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Finck</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Banner-Goodspeed</surname>
                      <given-names>VM</given-names>
                    </name>
                    <name>
                      <surname>Grissom</surname>
                      <given-names>CK</given-names>
                    </name>
                    <etal>
                      <italic>et al</italic>
                    </etal>
                  </person-group>
                  <collab>National Heart, Lung, and Blood Institute PETAL Clinical Trials
Network</collab>
                  <article-title>Early high-dose vitamin D<sub>3</sub> for critically ill, vitamin
D-deficient patients</article-title>
                  <source>
                    <italic>N Engl J Med</italic>
                  </source>
                  <year>2019</year>
                  <volume>381</volume>
                  <fpage>2529</fpage>
                  <lpage>2540</lpage>
                  <pub-id pub-id-type="pmid">31826336</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib51">
                <label>51 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McCullagh</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Regression models for ordinal data</article-title>
                  <source>
                    <italic>J R Stat Soc B</italic>
                  </source>
                  <year>1980</year>
                  <volume>42</volume>
                  <fpage>109</fpage>
                  <lpage>127</lpage>
                </mixed-citation>
              </ref>
              <ref id="bib52">
                <label>52 </label>
                <mixed-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harrell</surname>
                      <given-names>FE</given-names>
                      <suffix>Jr</suffix>
                    </name>
                  </person-group>
                  <source>Regression modeling strategies: with applications to linear models,
logistic and ordinal regression, and survival analysis.</source>
                  <publisher-loc>Heidelberg</publisher-loc>
                  <publisher-name>Springer</publisher-name>
                  <year>2015</year>
                </mixed-citation>
              </ref>
              <ref id="bib53">
                <label>53 </label>
                <mixed-citation publication-type="web">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harrell</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Lindsell</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Statistical design and analysis plan for randomized trial of
hydroxychloroquine for treatment of COVID-19;</article-title>
                  <year>2020</year>
                  <comment>[accessed 2020 Jun 9]. Available from: <ext-link ext-link-type="uri" xlink:href="http://hbiostat.org/proj/covid19/bayesplan.html">http://hbiostat.org/proj/covid19/bayesplan.html</ext-link></comment>
                </mixed-citation>
              </ref>
              <ref id="bib54">
                <label>54 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fayers</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Ashby</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Parmar</surname>
                      <given-names>MK</given-names>
                    </name>
                  </person-group>
                  <article-title>Tutorial in biostatistics Bayesian data monitoring in clinical
trials</article-title>
                  <source>
                    <italic>Stat Med</italic>
                  </source>
                  <year>1997</year>
                  <volume>16</volume>
                  <fpage>1413</fpage>
                  <lpage>1430</lpage>
                  <pub-id pub-id-type="pmid">9232762</pub-id>
                </mixed-citation>
              </ref>
              <ref id="bib55">
                <label>55 </label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hobbs</surname>
                      <given-names>BP</given-names>
                    </name>
                    <name>
                      <surname>Carlin</surname>
                      <given-names>BP</given-names>
                    </name>
                  </person-group>
                  <article-title>Practical Bayesian design and analysis for drug and device
clinical trials</article-title>
                  <source>
                    <italic>J Biopharm Stat</italic>
                  </source>
                  <year>2008</year>
                  <volume>18</volume>
                  <fpage>54</fpage>
                  <lpage>80</lpage>
                  <pub-id pub-id-type="pmid">18161542</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
